| Ytd | 37.49% | |
| 1y | -16.76% |
| Open | 28.75 | Prev Close | 28.88 | Low | 28.75 | High | 30.24 | Mkt Cap | 5.78B |
| Vol | 1.62M | Avg Vol | 2.75M | EPS | -1.38 | P/E | N/A | Forward P/E | 21.63 |
| Beta | 0.35 | Short Ratio | 4.78 | Inst. Own | 53.10% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 28.97 | 200-d Avg | 25.51 | 1yr Est | 57.43 |
LEGN News
Legend Biotech (LEGN) shares drop in premarket trading after pricing a $226M public offering. Get th
US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.
Smith & Wesson (SWBI) shares rose in pre-market trading after posting strong Q4 results, beating
Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a glob
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with re
UBS analyst Ashwani Verma maintains Legend Biotech (NASDAQ:LEGN) with a Buy and raises the price
Top Wall Street analysts changed outlook on top names. For all rating changes, upgrades and downgrad
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a
Promising Phase 1 data for LB2501, a potential first‑in‑class CD19/CD20 dual‑targeting in vivo CAR-T
LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors am